FAQs

Research reagents for HER2/ERBB2 studies in breast cancer, gastric cancer, and beyond. Covers target biology, HER2 signaling, IHC scoring, and available antibodies, proteins, and biosimilar reference antibodies.

Research reagents for EGFR/ERBB1 studies in lung cancer, CRC, and HNSCC. Covers EGFR signaling, mutation landscape, targeted therapies, and available antibodies, proteins, and biosimilars.

Research reagents for CD20 studies in lymphoma, leukemia, and autoimmune disease. Covers B cell biology, CD20-targeted therapies, and available antibodies, proteins, and biosimilars.

Research reagents for next-generation checkpoint targets LAG-3, TIGIT, and TIM-3. Covers biology, clinical development status, exhaustion phenotyping, and available antibodies, proteins, and biosimilars.

Research reagents for VEGF/VEGFR and angiogenesis studies. Covers the VEGF signaling axis, anti-angiogenic therapies, and available antibodies, proteins, and biosimilars.

Research reagents for costimulatory checkpoint agonists OX40 and 4-1BB. Covers target biology, agonist vs antagonist mechanisms, and available antibodies, proteins, and biosimilars.

Research reagents for TNF-alpha studies in inflammation and cancer. Covers TNF biology, anti-TNF therapeutics, and available antibodies, proteins, and biosimilars.

Research reagents for lung cancer (NSCLC/SCLC). Covers EGFR mutations, ALK/ROS1 fusions, PD-L1 expression, KRAS G12C, and emerging targets with matched antibodies, proteins, and biosimilars.

Research reagents for breast cancer subtypes. Covers HER2, ER/PR, BRCA1/2, Ki-67, TROP2, and PD-L1 with IHC, flow cytometry, and biosimilar reference antibodies.

Research reagents for colorectal cancer. Covers MSI/MMR markers (MLH1, MSH2, MSH6, PMS2), KRAS/BRAF mutations, EGFR targeting, CEA, and immunotherapy in CRC.